Ishares Gen-immunology Hlth (IDNA) Technical Analysis
$26.75▲1.21%
Market is closed - opens 8 PM, 25 Nov 2025
Insights
- Ishares Gen-immunology Hlth is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Ishares Gen-immunology Hlth stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Ishares Gen-immunology Hlth stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Ishares Gen-immunology Hlth stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 63.41 | Sell |
Stochastic | 91.63, 78.9 | Neutral |
Ultimate Oscillator | 52.93 | Neutral |
Stochastic Relative Strength Index | 55.4, 60.72 | Neutral |
Moving Average Convergence Divergence | 0.46, 0.44 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 26.01 | Buy |
20 | 25.54 | Buy |
50 | 24.58 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 25.93 | Buy |
20 | 25.58 | Buy |
50 | 24.7 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 26.02 | Neutral |
20 | 25.41 | Buy |
50 | 24.69 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 26.26 | Buy |
20 | 26.2 | Buy |
50 | 25.97 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 26.28 | Buy |
20 | 26.25 | Sell |
50 | 26.27 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 26.95 |
Resistance L2 | 26.72 |
Resistance L1 | 26.28 |
Pivot Point | 26.05 |
Support L1 | 25.61 |
Support L2 | 25.39 |
Support L3 | 24.94 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.